Lovende utvikling og ingen emisjon i 2025
Pcib har fått gode svar og går inn i en spennende fase for utforskning av samarbeid og kommersialisering
fabian2
02.02.2025 kl 17:56
491
Ja , selvsagt opsjoner , ikke aksjer ,sorry. Hvis det nå skjer « noe « så er det nok ikke mange minuttene opp til 4 kr. Tror det blir inneværende år…..og kanskje mye mer enn 4 kr……det er bare 4 - 5 år siden kursen var over 80….men selvsagt med andre forutsetninger da. Nå holder de jo på med andre ting. Kanskje 10 kr e r kursen om et halvt år…….»ken så veit»
Oksenbull
02.02.2025 kl 14:12
554
Det er ikkje aksjer, men opsjoner som kan innløses en gang i fremtiden. Det skaper insentiv til å gjøre det godt, for har man 560.000 opsjoner til en strike 1.35 kr og de kan innløses q3 i 25, og aksjekursen er 4kr vil det klart lønna seg. Så bra dei har opsjonsprogram, det viser at ledelsen lønner seg med å skape aksjonærverdier fremover. Merkar meg at cashbeholdningen holder lengre ann vi har hadde forventet til H2 2025, så nå er Partner Dependent periode og mulighet for å scalere opp eller selge PCI grunnlaget om det skulle lønnet seg.
fabian2
02.02.2025 kl 13:20
599
Siden aksjer koster bare 1.26 nå….så skal det ikke store nyheten til før den går noen hundre prosent opp. En av sjefene har 560.000 aksjer. Det er nok en grunn. Se melding 10.januar
Redigert 02.02.2025 kl 13:51
Du må logge inn for å svare
X-43 scramjet
28.08.2024 kl 17:53
1526
Thermo Fisher Scientific, Viral Vector Production, Innovations in Gene Therapy.
Thermo Fisher og Lonza, mulig et av de pharma selskapene ønsker samarbeid med PCIB. Spennende å se hva som kommer neste
X-43 scramjet
28.08.2024 kl 09:58
1913
Oslo (Norway), 28 August 2024 -- PCI Biotech (OSE: PCIB), today announces its interim first half 2024 results. Please find enclosed the interim report and presentation.
Highlights review
Operations
"PCI Biotech's 2024 development goals are to demonstrate scalability and manufacturing process benefits for the photochemical-based technology (PCL) in viral vector manufacturing.
Results reported in Q1 2024 from field testing of the technology with a European partner confirmed the potential benefit of applying photochemical methods in viral vector (AAV) manufacturing. These results are considered an important interim scalability milestone, warranting further development.
To accelerate further scale-up of the PCL technology, PCI Biotech is currently working with a renowned ATMP-sector service provider to advance the technology into mini benchtop bioreactors, which are considered representative for large-scale manufacturing.
Initial mini benchtop bioreactor results indicate that PCL is compatible with standard downstream processes. Further research is needed to demonstrate PCL's manufacturing benefit and achieve the 2024 development goals.
Corporate
The cash position of NOK 30.5 million per end of June 2024 is estimated to support operations into 2H 2025 with current plans, providing an opportunity window to demonstrate the commercial potential of the technology platform.
Ronny Skuggedal, CEO of PCI Biotech, comments: "After receiving encouraging early-stage field testing feedback at the beginning of this year, we accelerated development by successfully transferring PCL to a renowned service provider for scale-up to mini benchtop bioreactor**.**An initial mini benchtop bioreactor run gave important indications of PCL's compatibility with standard downstream manufacturing processes, a reverting topic in business development discussions. We are eager to continue working at this scale."
Highlights review
Operations
"PCI Biotech's 2024 development goals are to demonstrate scalability and manufacturing process benefits for the photochemical-based technology (PCL) in viral vector manufacturing.
Results reported in Q1 2024 from field testing of the technology with a European partner confirmed the potential benefit of applying photochemical methods in viral vector (AAV) manufacturing. These results are considered an important interim scalability milestone, warranting further development.
To accelerate further scale-up of the PCL technology, PCI Biotech is currently working with a renowned ATMP-sector service provider to advance the technology into mini benchtop bioreactors, which are considered representative for large-scale manufacturing.
Initial mini benchtop bioreactor results indicate that PCL is compatible with standard downstream processes. Further research is needed to demonstrate PCL's manufacturing benefit and achieve the 2024 development goals.
Corporate
The cash position of NOK 30.5 million per end of June 2024 is estimated to support operations into 2H 2025 with current plans, providing an opportunity window to demonstrate the commercial potential of the technology platform.
Ronny Skuggedal, CEO of PCI Biotech, comments: "After receiving encouraging early-stage field testing feedback at the beginning of this year, we accelerated development by successfully transferring PCL to a renowned service provider for scale-up to mini benchtop bioreactor**.**An initial mini benchtop bioreactor run gave important indications of PCL's compatibility with standard downstream manufacturing processes, a reverting topic in business development discussions. We are eager to continue working at this scale."